Canaccord Genuity Maintains Buy on Ultragenyx Pharmaceutical, Raises Price Target to $39
Benzinga Newsdesk 1 month ago
Analyst RatingsNewsPrice Target
Canaccord Genuity analyst Whitney Ijem maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Buy and raises the price target from $37 to $39.
Canaccord Genuity analyst Whitney Ijem maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Buy and raises the price target from $37 to $39.